| Bioactivity | RLY-2608 is a first-in-class allosteric mutant-selective inhibitor of PI3Ka[1]. |
| Name | RLY-2608 |
| CAS | 2733573-94-7 |
| Formula | C29H14ClF5N6O2 |
| Molar Mass | 608.91 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Andreas Varkaris, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer Discov. 2023 Nov 2. |